Navigation Links
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

ion resistant prostate cancer and bone metastases, and these data encourage further exploration of the ability of tumor antigen release by radiotherapy to serve as an immune-supportive intervention in combination with ipilimumab as a potentially important treatment option for these patients."

The Phase 1/2 trial was conducted to evaluate the safety and preliminary anti-tumor activity of escalating doses of ipilimumab (3, 5 or 10 mg/kg) every three weeks for up to four doses, with and without a single dose of focal radiotherapy administered to target bone lesion(s) prior to the first dose of ipilimumab. The dose escalation portion of the trial enrolled 33 patients with mCRPC and with bone metastases. Additional patients are enrolling in the expansion cohort of 10mg/kg ipilimumab in combination with radiotherapy.

Adverse events related to ipilimumab in this study were generally manageable and consistent with those immune-related adverse events (irAEs) previously reported in other clinical trials of ipilimumab. Grade 3/4 adverse events included diarrhea/colitis (5 patients), rash (1 patient) and elevated liver enzymes (2 patients). No new patterns or frequency of adverse events emerged in patients receiving the combination of ipilimumab and radiotherapy.

About Ipilimumab

Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that plays a critical role in regulating natural immune responses. The absence or presence of CTLA- 4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells.

Comprehensive Clinical Trial Program for Ipilimumab

Bristol-Myers Squibb Company and Medarex remain committed to the development of ipilimumab. The companies also have ongoing Phase 2 studies in hormone-refractory prostate canc
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
6. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
7. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
8. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
9. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
10. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015   Decision Resources Group ... in dialysis patient management in the U.S. versus ... by U.S. and EU5 nephrologists from approximately 1,870 ... are the most commonly used renal medications in ... differs considerably between the two regions.      ...
(Date:7/7/2015)... FRANCISCO , July 7, 2015 ... reach USD 1,197.7 million by 2020, growing at an estimated ... new study by Grand View Research, Inc. Introduction of innovative ... coupled with growing awareness levels pertaining to the advantages of ... the next six years. In addition, presence of untapped growth ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... CHICAGO and ORANGE, Calif., Feb. 23, 2011 ... (SJHS), a $4.6 billion not-for-profit Catholic healthcare system based in ... in California, West Texas and Eastern New Mexico, has selected ... MDRX ) to streamline patient movement through their ...
... Caliper Life Sciences, Inc. (Nasdaq: ... announced a co-marketing agreement which will leverage Covaris, ... microfluidics technologies to develop automated workflows for next ... suite of solutions for library construction, sample analysis, ...
Cached Medicine Technology:St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 2St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 3St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 4St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 5Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 2Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 3
(Date:7/7/2015)... ... July 07, 2015 , ... Owners of Green Ladies Cleaning are very ... home service category. This honor can only be gained by votes from Madison Magazine ... of the products and methods they use daily. Having a home cleaned with all-natural ...
(Date:7/7/2015)... ... July 07, 2015 , ... This ... debuting their brand new website. The website’s goal is to provide patients with ... of patient tools, including requesting appointments online. , Part of the center’s rebranding ...
(Date:7/7/2015)... ... July 07, 2015 , ... Celestix Networks, ... VE and CelestixFederated VA Series virtual appliances. These virtual platforms expand the ... products, which have proven to simplify the on-premises deployment of unified remote access ...
(Date:7/7/2015)... ... 07, 2015 , ... At the end of June Pacific Prime Renewals team in Hong Kong ... initiative, spearheaded by the Renewals Manager, Danielle Cotton, aims to not only reduce but eventually ... initiative Cotton explained, “We send anything between 300 and 600 pieces of paper per month. ...
(Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, ... at the Manistee Golf and Country Club. Best Drug Rehabilitation staff members were delighted ... cause, helping underprivileged children. Kiwanis International, the parent of the Manistee Kiwanis Club, is ...
Breaking Medicine News(10 mins):Health News:Environmentally-Friendly House Cleaning Company Wins Best of Madison Magazine Award 2Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 2Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 3Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 4Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2
... breast biopsies for patients with early breast cancer, helping ... undergoing a second breast cancer surgery, a new study ... a sentinel lymph node biopsy to determine if their ... of the study. Ultrasound, on its own, can,t ...
... Reinberg HealthDay Reporter , MONDAY, Jan. 31 ... to those of humans, dogs can sniff out buried ... They can also apparently detect colorectal cancer, Japanese researchers ... that a specially trained 8-year-old female Labrador retriever named ...
... High levels of circulating DNA may indicate faster progression ... a study published in the February edition of the ... of the International Association for the Study of Lung ... that cancer patients presented more free DNA in the ...
... , MONDAY, Jan. 31 (HealthDay News) -- Women who begin ... for breast cancer than those who start the treatment later, ... earlier studies had concluded that hormone therapy increases breast cancer ... the therapy influences that risk, something they said few studies ...
... , MONDAY, Jan. 31 (HealthDay News) -- Hands-on ... in highly hazardous jobs, according to a new study. ... took part in 113 safety training studies conducted since 1971. ... severe illness, injury or death. In jobs where the ...
... ANN ARBOR, Mich.--Brain scans showing neural reactions to pro-health ... quit smoking more accurately than you yourself can. ... Psychology, a peer-reviewed journal. , "We targeted smokers who ... the lead author of the study and director of ...
Cached Medicine News:Health News:Microbubble ultrasound and breast biopsies 2Health News:Trained Labrador Can Sniff Out Colon Cancer, Researchers Say 2Health News:Trained Labrador Can Sniff Out Colon Cancer, Researchers Say 3Health News:Trained Labrador Can Sniff Out Colon Cancer, Researchers Say 4Health News:High levels of circulating DNA may signal faster progression of lung cancer 2Health News:Hands-On Training May Save Workers in Hazardous Jobs 2Health News:Resolved to quit smoking? 2
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
Medicine Products: